Liu Yu, Xu Jing-Song, Cao Li, Yang Shuang, Li Tian-Ming, Huang Hai-Qian, Zhang Jun-Heng, Zhao Xue, Liu Qian, Li Shun, Li Min, Wang Hua
Department of Laboratory Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.
Department of Pathology, the Fifth People's Hospital of Shanghai, Fudan University, Shanghai, 200240, China.
Mil Med Res. 2025 Aug 4;12(1):44. doi: 10.1186/s40779-025-00632-0.
Organ transplantation recipients encounter significant risks from acute or chronic infections that threaten graft survival. BK virus (BKV) and JC virus (JCV) are two prominent opportunistic infection viruses, and they may cause polyomavirus-associated nephropathy and graft kidney loss in patients who are in an immunosuppressed state after kidney transplantation. Hence, timely detection and sustained monitoring of the viral load are indispensable. However, the current diagnostic methods remain limited, and the development of new molecular detection technology is extremely urgent.
The sequences and concentrations of clustered regularly interspaced short palindromic repeats (CRISPR) RNA (crRNA), the concentration of Cas13a, and the primers for recombinase polymerase amplification (RPA) were optimized for BKV and JCV detection. Next, a novel microfluidic dual-droplet chip was designed and fabricated, and it was integrated with CRISPR (ddCRISPR) to simultaneously qualitatively detect BKV and JCV. Subsequently, the ddCRISPR assay was verified using clinical samples. Then, a lateral flow strip combined with CRISPR (LFCRISPR) was developed for the detection of BKV and JCV in resource-limited settings.
A one-pot RPA-CRISPR reaction system was established and optimized for BKV and JCV detection. ddCRISPR can simultaneously and rapidly detect BKV and JCV with high sensitivity (10 copies/ml for BKV and 1 copy/ml for JCV), and provide absolute quantification, which is suitable for viral load detection and conducive to personalized and precise treatment for organ transplant recipients. LFCRISPR simplified the operational process through a simple visual readout, facilitating virus screening after organ transplantation.
These platforms incorporate molecular testing into the transplantation treatment model, thereby reducing costs, prolonging the survival time of the graft, improving the clinical outcomes of postoperative management in kidney transplantation, and enhancing the patients' quality of life.
器官移植受者面临急性或慢性感染带来的重大风险,这些感染会威胁移植器官的存活。BK病毒(BKV)和JC病毒(JCV)是两种主要的机会性感染病毒,它们可能导致肾移植后处于免疫抑制状态的患者发生多瘤病毒相关性肾病和移植肾丢失。因此,及时检测和持续监测病毒载量是必不可少的。然而,目前的诊断方法仍然有限,新型分子检测技术的开发迫在眉睫。
对用于检测BKV和JCV的成簇规律间隔短回文重复序列(CRISPR)RNA(crRNA)的序列和浓度、Cas13a的浓度以及重组酶聚合酶扩增(RPA)引物进行了优化。接下来,设计并制造了一种新型微流控双液滴芯片,并将其与CRISPR(ddCRISPR)集成,以同时定性检测BKV和JCV。随后,使用临床样本对ddCRISPR检测法进行了验证。然后,开发了一种结合CRISPR的侧向流动试纸条(LFCRISPR),用于在资源有限的环境中检测BKV和JCV。
建立并优化了一种用于检测BKV和JCV的一锅法RPA-CRISPR反应系统。ddCRISPR能够同时快速检测BKV和JCV,灵敏度高(BKV为10拷贝/毫升,JCV为1拷贝/毫升),并能进行绝对定量,适用于病毒载量检测,有利于器官移植受者的个性化精准治疗。LFCRISPR通过简单的视觉读数简化了操作过程,便于器官移植后的病毒筛查。
这些平台将分子检测纳入移植治疗模式,从而降低成本,延长移植器官的存活时间,改善肾移植术后管理的临床结果,并提高患者的生活质量。